Lawrence Steinman

Back to Profile

Publication Details

  • Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

    Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L. Ann Neurol. 2008; 63 (5): 611-20

    To evaluate the efficacy and safety of BHT-3009 in relapsing-remitting multiple sclerosis (MS) and to confirm that BHT-3009 causes immune tolerance.

    PubMedID: 18481290

Stanford Medicine Resources:

Footer Links: